Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New research paves way for personalised breast cancer drug

  • Comment

‘Made-to-measure’ cancer treatment could be a step closer after scientists developed a way to predict responses to a breast cancer drug, it has been reported.

The report showed that the drug Herceptin is used to treat breast cancer, but its efficacy can vary from case to case. Researchers at Edinburgh University claim to have created a model which predicts this reaction.

The amount of the protein HER2 found in cancer cells currently determines whether the drug is used, while scientists also claim to have identified a different protein involved in resisting treatment.

After examining 122 samples of metastatic breast cancer, the Breakthrough Breast Cancer research unit found patients with high levels of the resistance protein survived 22 months longer than those with low levels.

Writing in the journal Cancer Research, pathologist Dr Dana Faratian said: ‘The impact of this new approach could be huge.

‘It shows we can use computer modelling to answer clinical questions and potentially refine the treatment of women with breast cancer.’

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs